Please login to the form below

Not currently logged in
Email:
Password:

abatacept

This page shows the latest abatacept news and features for those working in and with pharma, biotech and healthcare.

Opdivo drives growth at BMS, but US sales slow down

Opdivo drives growth at BMS, but US sales slow down

abatacept), which was up 16% to $625m.

Latest news

More from news
Approximately 5 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • BMS’ Brian Daniels to retire BMS’ Brian Daniels to retire

    Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics